Medintech develops a motorized, 50% lighter gastrointestinal endoscope and complementary AI software to detect abnormal regions and reduce misdiagnosis. The company’s founders spun out of the Korea Electrotechnology Research Institute and established the business in 2020. It holds Class II medical device approval for its motorized GI endoscope system and its anomaly‑detection software. Medintech is conducting clinical trials with Seoul National University Hospital and plans full market entry within the year. The company intends to further refine its AI convenience features to maximize the utility and ease of its motorized endoscope. Proceeds from its latest financing will be used to establish mass production capabilities and support overseas expansion. Cumulatively, Medintech has raised more than ₩28 billion to date.

Total raised

$15M

Funding rounds

1

Latest round

Series B

Latest activity

May 2024